JP2017501400A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501400A5 JP2017501400A5 JP2016536629A JP2016536629A JP2017501400A5 JP 2017501400 A5 JP2017501400 A5 JP 2017501400A5 JP 2016536629 A JP2016536629 A JP 2016536629A JP 2016536629 A JP2016536629 A JP 2016536629A JP 2017501400 A5 JP2017501400 A5 JP 2017501400A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer
- biomarker
- cell
- polymorph
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 20
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 14
- 239000000090 biomarker Substances 0.000 claims 8
- 108010050904 Interferons Proteins 0.000 claims 7
- 102000014150 Interferons Human genes 0.000 claims 7
- 229940079322 interferon Drugs 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 239000013078 crystal Substances 0.000 claims 5
- 235000018102 proteins Nutrition 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 4
- 230000037361 pathway Effects 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 claims 3
- 102100032783 Protein cereblon Human genes 0.000 claims 3
- 239000000523 sample Substances 0.000 claims 3
- 102100035389 2'-5'-oligoadenylate synthase 3 Human genes 0.000 claims 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 2
- YMZPQKXPKZZSFV-CPWYAANMSA-N 2-[3-[(1r)-1-[(2s)-1-[(2s)-2-[(1r)-cyclohex-2-en-1-yl]-2-(3,4,5-trimethoxyphenyl)acetyl]piperidine-2-carbonyl]oxy-3-(3,4-dimethoxyphenyl)propyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H]([C@H]2C=CCCC2)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 YMZPQKXPKZZSFV-CPWYAANMSA-N 0.000 claims 2
- GTVAUHXUMYENSK-RWSKJCERSA-N 2-[3-[(1r)-3-(3,4-dimethoxyphenyl)-1-[(2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)pent-4-enoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC=C)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GTVAUHXUMYENSK-RWSKJCERSA-N 0.000 claims 2
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 claims 2
- 102100034357 Casein kinase I isoform alpha Human genes 0.000 claims 2
- 229940126062 Compound A Drugs 0.000 claims 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 2
- 101000597332 Homo sapiens 2'-5'-oligoadenylate synthase 3 Proteins 0.000 claims 2
- 101000952099 Homo sapiens Antiviral innate immune response receptor RIG-I Proteins 0.000 claims 2
- 101000994700 Homo sapiens Casein kinase I isoform alpha Proteins 0.000 claims 2
- 101000840275 Homo sapiens Interferon alpha-inducible protein 27, mitochondrial Proteins 0.000 claims 2
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 claims 2
- 101001032342 Homo sapiens Interferon regulatory factor 7 Proteins 0.000 claims 2
- 101001082065 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 1 Proteins 0.000 claims 2
- 101001082060 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 3 Proteins 0.000 claims 2
- 101001057508 Homo sapiens Ubiquitin-like protein ISG15 Proteins 0.000 claims 2
- 108010044240 IFIH1 Interferon-Induced Helicase Proteins 0.000 claims 2
- 102100029604 Interferon alpha-inducible protein 27, mitochondrial Human genes 0.000 claims 2
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 claims 2
- 102100038070 Interferon regulatory factor 7 Human genes 0.000 claims 2
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 claims 2
- 102100027355 Interferon-induced protein with tetratricopeptide repeats 1 Human genes 0.000 claims 2
- 102100027302 Interferon-induced protein with tetratricopeptide repeats 3 Human genes 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 102100027266 Ubiquitin-like protein ISG15 Human genes 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 2
- 229960004942 lenalidomide Drugs 0.000 claims 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 2
- 229960000688 pomalidomide Drugs 0.000 claims 2
- 239000013074 reference sample Substances 0.000 claims 2
- 229960003433 thalidomide Drugs 0.000 claims 2
- 102100027769 2'-5'-oligoadenylate synthase 1 Human genes 0.000 claims 1
- 102100027621 2'-5'-oligoadenylate synthase 2 Human genes 0.000 claims 1
- 102100035473 2'-5'-oligoadenylate synthase-like protein Human genes 0.000 claims 1
- GXAFMKJFWWBYNW-OWHBQTKESA-N 2-[3-[(1r)-1-[(2s)-1-[(2s)-3-cyclopropyl-2-(3,4,5-trimethoxyphenyl)propanoyl]piperidine-2-carbonyl]oxy-3-(3,4-dimethoxyphenyl)propyl]phenoxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1CC[C@H](C=1C=C(OCC(O)=O)C=CC=1)OC(=O)[C@H]1N(C(=O)[C@@H](CC2CC2)C=2C=C(OC)C(OC)=C(OC)C=2)CCCC1 GXAFMKJFWWBYNW-OWHBQTKESA-N 0.000 claims 1
- RSNPAKAFCAAMBH-UHFFFAOYSA-N 3-(5-amino-2-methyl-4-oxoquinazolin-3-yl)piperidine-2,6-dione Chemical compound CC1=NC2=CC=CC(N)=C2C(=O)N1C1CCC(=O)NC1=O RSNPAKAFCAAMBH-UHFFFAOYSA-N 0.000 claims 1
- IXZOHGPZAQLIBH-UHFFFAOYSA-N 3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1h-isoindol-2-yl]piperidine-2,6-dione Chemical compound O=C1N(C2C(NC(=O)CC2)=O)CC2=C1C=CC=C2OCC(C=C1)=CC=C1CN1CCOCC1 IXZOHGPZAQLIBH-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 102100021069 E3 ubiquitin-protein ligase ZFP91 Human genes 0.000 claims 1
- 101710120623 FERM, ARHGEF and pleckstrin domain-containing protein 2 Proteins 0.000 claims 1
- 102100039928 Gamma-interferon-inducible protein 16 Human genes 0.000 claims 1
- 102100035688 Guanylate-binding protein 1 Human genes 0.000 claims 1
- 101001008907 Homo sapiens 2'-5'-oligoadenylate synthase 1 Proteins 0.000 claims 1
- 101001008910 Homo sapiens 2'-5'-oligoadenylate synthase 2 Proteins 0.000 claims 1
- 101000597360 Homo sapiens 2'-5'-oligoadenylate synthase-like protein Proteins 0.000 claims 1
- 101000818429 Homo sapiens E3 ubiquitin-protein ligase ZFP91 Proteins 0.000 claims 1
- 101000960209 Homo sapiens Gamma-interferon-inducible protein 16 Proteins 0.000 claims 1
- 101001001336 Homo sapiens Guanylate-binding protein 1 Proteins 0.000 claims 1
- 101001034835 Homo sapiens Interferon alpha-16 Proteins 0.000 claims 1
- 101000959704 Homo sapiens Interferon alpha-5 Proteins 0.000 claims 1
- 101001037247 Homo sapiens Interferon alpha-inducible protein 27-like protein 2 Proteins 0.000 claims 1
- 101001082070 Homo sapiens Interferon alpha-inducible protein 6 Proteins 0.000 claims 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 claims 1
- 101001001420 Homo sapiens Interferon gamma receptor 1 Proteins 0.000 claims 1
- 101000598002 Homo sapiens Interferon regulatory factor 1 Proteins 0.000 claims 1
- 101001011382 Homo sapiens Interferon regulatory factor 3 Proteins 0.000 claims 1
- 101001032345 Homo sapiens Interferon regulatory factor 8 Proteins 0.000 claims 1
- 101001032341 Homo sapiens Interferon regulatory factor 9 Proteins 0.000 claims 1
- 101000998500 Homo sapiens Interferon-induced 35 kDa protein Proteins 0.000 claims 1
- 101001128393 Homo sapiens Interferon-induced GTP-binding protein Mx1 Proteins 0.000 claims 1
- 101000840293 Homo sapiens Interferon-induced protein 44 Proteins 0.000 claims 1
- 101000959664 Homo sapiens Interferon-induced protein 44-like Proteins 0.000 claims 1
- 101001082058 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 2 Proteins 0.000 claims 1
- 101001082063 Homo sapiens Interferon-induced protein with tetratricopeptide repeats 5 Proteins 0.000 claims 1
- 101001034842 Homo sapiens Interferon-induced transmembrane protein 2 Proteins 0.000 claims 1
- 101001034846 Homo sapiens Interferon-induced transmembrane protein 3 Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101000952078 Homo sapiens Probable ATP-dependent RNA helicase DDX60 Proteins 0.000 claims 1
- 101000952073 Homo sapiens Probable ATP-dependent RNA helicase DDX60-like Proteins 0.000 claims 1
- 101000665442 Homo sapiens Serine/threonine-protein kinase TBK1 Proteins 0.000 claims 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 claims 1
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 claims 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims 1
- 101000814514 Homo sapiens XIAP-associated factor 1 Proteins 0.000 claims 1
- 102100039728 Interferon alpha-16 Human genes 0.000 claims 1
- 102100039948 Interferon alpha-5 Human genes 0.000 claims 1
- 102100040063 Interferon alpha-inducible protein 27-like protein 2 Human genes 0.000 claims 1
- 102100027354 Interferon alpha-inducible protein 6 Human genes 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 102100035678 Interferon gamma receptor 1 Human genes 0.000 claims 1
- 102100036981 Interferon regulatory factor 1 Human genes 0.000 claims 1
- 102100029843 Interferon regulatory factor 3 Human genes 0.000 claims 1
- 102100038069 Interferon regulatory factor 8 Human genes 0.000 claims 1
- 102100038251 Interferon regulatory factor 9 Human genes 0.000 claims 1
- 102100033273 Interferon-induced 35 kDa protein Human genes 0.000 claims 1
- 102100031802 Interferon-induced GTP-binding protein Mx1 Human genes 0.000 claims 1
- 102100029607 Interferon-induced protein 44 Human genes 0.000 claims 1
- 102100039953 Interferon-induced protein 44-like Human genes 0.000 claims 1
- 102100027303 Interferon-induced protein with tetratricopeptide repeats 2 Human genes 0.000 claims 1
- 102100027356 Interferon-induced protein with tetratricopeptide repeats 5 Human genes 0.000 claims 1
- 102100040020 Interferon-induced transmembrane protein 2 Human genes 0.000 claims 1
- 102100040035 Interferon-induced transmembrane protein 3 Human genes 0.000 claims 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 102100033008 Poly(U)-binding-splicing factor PUF60 Human genes 0.000 claims 1
- 102100037439 Probable ATP-dependent RNA helicase DDX60 Human genes 0.000 claims 1
- 102100037440 Probable ATP-dependent RNA helicase DDX60-like Human genes 0.000 claims 1
- 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 claims 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 claims 1
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 claims 1
- 102100027010 Toll-like receptor 1 Human genes 0.000 claims 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims 1
- 102100039488 XIAP-associated factor 1 Human genes 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913003P | 2013-12-06 | 2013-12-06 | |
| US61/913,003 | 2013-12-06 | ||
| US201461947963P | 2014-03-04 | 2014-03-04 | |
| US61/947,963 | 2014-03-04 | ||
| US201461990621P | 2014-05-08 | 2014-05-08 | |
| US61/990,621 | 2014-05-08 | ||
| US201462061050P | 2014-10-07 | 2014-10-07 | |
| US62/061,050 | 2014-10-07 | ||
| US201462064413P | 2014-10-15 | 2014-10-15 | |
| US62/064,413 | 2014-10-15 | ||
| US201462077835P | 2014-11-10 | 2014-11-10 | |
| US62/077,835 | 2014-11-10 | ||
| US201462087111P | 2014-12-03 | 2014-12-03 | |
| US62/087,111 | 2014-12-03 | ||
| PCT/US2014/068795 WO2015085172A2 (en) | 2013-12-06 | 2014-12-05 | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019120643A Division JP7142612B2 (ja) | 2013-12-06 | 2019-06-28 | びまん性大細胞型ｂ細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017501400A JP2017501400A (ja) | 2017-01-12 |
| JP2017501400A5 true JP2017501400A5 (enExample) | 2018-01-18 |
| JP6573611B2 JP6573611B2 (ja) | 2019-09-11 |
Family
ID=53274285
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536629A Active JP6573611B2 (ja) | 2013-12-06 | 2014-12-05 | びまん性大細胞型ｂ細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法 |
| JP2019120643A Active JP7142612B2 (ja) | 2013-12-06 | 2019-06-28 | びまん性大細胞型ｂ細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019120643A Active JP7142612B2 (ja) | 2013-12-06 | 2019-06-28 | びまん性大細胞型ｂ細胞リンパ腫、多発性骨髄腫、及び骨髄癌の治療の薬効を決定するための方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20160313300A1 (enExample) |
| EP (1) | EP3077548B1 (enExample) |
| JP (2) | JP6573611B2 (enExample) |
| KR (1) | KR102299801B1 (enExample) |
| AU (1) | AU2014360328B2 (enExample) |
| BR (1) | BR112016012795A2 (enExample) |
| CA (2) | CA2932120C (enExample) |
| EA (1) | EA201691144A1 (enExample) |
| ES (1) | ES2903155T3 (enExample) |
| IL (2) | IL278381B2 (enExample) |
| MX (1) | MX386337B (enExample) |
| PH (1) | PH12016501041A1 (enExample) |
| WO (1) | WO2015085172A2 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE035389T2 (en) | 2006-09-26 | 2018-05-02 | Celgene Corp | 5-substituted quinazolinone derivatives as anticancer agents |
| SG183257A1 (en) | 2010-02-11 | 2012-09-27 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| RU2611007C2 (ru) | 2011-03-11 | 2017-02-17 | Селджин Корпорейшн | Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона и их фармацевтические композиции и применение |
| WO2014039421A1 (en) | 2012-09-04 | 2014-03-13 | Celgene Corporation | Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof |
| US9695145B2 (en) | 2013-01-22 | 2017-07-04 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| ES2738289T3 (es) | 2013-11-06 | 2020-01-21 | Hospital Clinic Barcelona | Procedimiento para el subtipado de tipos de linfoma por medio de perfiles de expresión |
| WO2015085172A2 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| ES2843973T3 (es) | 2014-06-27 | 2021-07-21 | Celgene Corp | Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3 |
| EP3277272B1 (en) | 2015-03-31 | 2021-08-04 | Syros Pharmaceuticals, Inc. | Methods of stratifying patients for treatment with retinoic acid receptor-agonists |
| WO2016196580A1 (en) | 2015-06-02 | 2016-12-08 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
| US20170038387A1 (en) * | 2015-08-04 | 2017-02-09 | Celgene Corporation | Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| US20180231561A1 (en) * | 2015-08-12 | 2018-08-16 | Celgene Corporation | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| AU2016326499A1 (en) * | 2015-09-25 | 2018-04-12 | Celgene Corporation | Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| WO2017100259A1 (en) * | 2015-12-08 | 2017-06-15 | Icahn School Of Medicine At Mount Sinai | Pretransplant prediction of post-transplant acute rejection |
| US10830762B2 (en) | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
| EP3399980B1 (en) | 2016-01-08 | 2025-07-16 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| WO2017143237A1 (en) * | 2016-02-17 | 2017-08-24 | Acetylon Pharmaceuticals, Inc. | Increasing expression of interferon regulated genes with combinatons of histone deacetylase inhibitors and immunomodulatory drugs |
| KR20240157122A (ko) * | 2016-04-08 | 2024-10-31 | 사이로스 파마수티컬스, 인크. | Aml 및 mds 치료용 rara 효능제 |
| ES2859423T3 (es) | 2016-04-20 | 2021-10-04 | Us Health | Evaluación del linfoma de células del manto y procedimientos relacionados con el mismo |
| SG10201607303YA (en) * | 2016-09-01 | 2018-04-27 | Agency Science Tech & Res | Antisense oligonucleotides to induce exon skipping |
| US20200078400A1 (en) | 2016-12-03 | 2020-03-12 | Juno Therapeutics, Inc. | Methods for determining car-t cells dosing |
| JP2019536460A (ja) | 2016-12-03 | 2019-12-19 | ジュノー セラピューティクス インコーポレイテッド | Ｃａｒ−ｔ細胞の調節方法 |
| US20180238886A1 (en) * | 2017-01-31 | 2018-08-23 | Celgene Corporation | Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds |
| US11266677B2 (en) * | 2017-03-10 | 2022-03-08 | Memorial Sloan Kettering Cancer Center | Methods for treatment or prevention of leukemia |
| PL3618842T3 (pl) | 2017-05-01 | 2024-02-19 | Juno Therapeutics, Inc. | Kombinacja terapii komórkowej i związku immunomodulującego |
| IL327498A (en) | 2017-06-02 | 2026-05-01 | Juno Therapeutics Inc | Articles of manufacture and methods for treatment using adoptive cell therapy |
| CN111050545A (zh) | 2017-06-29 | 2020-04-21 | 朱诺治疗学股份有限公司 | 评估与免疫疗法相关的毒性的小鼠模型 |
| WO2019079360A1 (en) * | 2017-10-16 | 2019-04-25 | Massachusetts Institute Of Technology | ATLAS OF HEALTHY AND ILLUMINATED TISSUE CELLS |
| WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| MA49911A (fr) | 2017-11-01 | 2020-06-24 | Juno Therapeutics Inc | Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b |
| MA51210A (fr) | 2017-12-01 | 2020-10-07 | Juno Therapeutics Inc | Procédés de dosage et de modulation de cellules génétiquement modifiées |
| EP3724225A1 (en) | 2017-12-15 | 2020-10-21 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
| CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| CN110448548B (zh) * | 2018-05-08 | 2023-05-05 | 四川大学华西医院 | Ifitm2抑制剂在制备治疗乙型肝炎的药物中的用途 |
| IL278854B2 (en) * | 2018-05-23 | 2026-01-01 | Celgene Corp | Multiple myeloma treatment and biomarker use for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl-3-fluorobenzonitrile |
| CN113573719A (zh) | 2018-11-08 | 2021-10-29 | 朱诺治疗学股份有限公司 | 治疗和t细胞调节的方法和组合 |
| BR112021009420A2 (pt) | 2018-11-16 | 2021-11-23 | Juno Therapeutics Inc | Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b |
| EP4427810A3 (en) | 2018-11-30 | 2024-12-04 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
| CN109583222A (zh) * | 2018-12-07 | 2019-04-05 | 浪潮(北京)电子信息产业有限公司 | 分布式文件系统元数据服务器回收客户端权限方法及装置 |
| EA202192103A1 (ru) | 2019-01-29 | 2021-12-15 | Джуно Терапьютикс, Инк. | Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1) |
| KR102947433B1 (ko) | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| WO2020231937A1 (en) * | 2019-05-10 | 2020-11-19 | University Of Massachusetts | Irf2 as a prognostic biomarker and target for augmenting immunotherapy |
| AU2020315775A1 (en) * | 2019-07-19 | 2022-02-24 | Pascal Biosciences (Us), Inc. | Composition and methods of targeting the pre-B cell receptor for the treatment of leukemias and lymphomas |
| HRP20231487T1 (hr) * | 2019-10-21 | 2024-03-01 | Celgene Corporation | Postupci za liječenje hematoloških malignosti uporabom 2-(2,6-dioksopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)izoindolin-1,3-diona |
| WO2021102420A1 (en) * | 2019-11-22 | 2021-05-27 | The Regents Of The University Of California | Interferon signaling as a cancer biomarker |
| KR20220110243A (ko) * | 2019-12-02 | 2022-08-05 | 셀진 코포레이션 | 암의 치료를 위한 요법 |
| EP4073517A1 (en) * | 2019-12-11 | 2022-10-19 | Erasmus University Rotterdam Medical Center | Method for monitoring of deep remissions in multiple myeloma and other plasma cell dyscrasias |
| CN111187755B (zh) * | 2020-02-20 | 2021-10-22 | 中国人民解放军军事科学院军事医学研究院 | 抗tpd52单克隆抗体杂交瘤细胞株及其单克隆抗体与应用 |
| US11366101B1 (en) | 2020-12-31 | 2022-06-21 | Elephas Biosciences Corporation | Ex vivo systems and methods for determining the effect of a drug or other agent on a tissue |
| CN117242060B (zh) | 2021-01-13 | 2026-07-17 | 蒙特罗莎治疗股份有限公司 | 异吲哚啉酮化合物 |
| CA3209784A1 (en) * | 2021-02-03 | 2022-08-11 | Curis Inc. | Biomarkers for fimepinostat therapy |
| KR102629955B1 (ko) * | 2021-02-19 | 2024-01-25 | 가톨릭대학교 산학협력단 | Ewsr1의 발현 또는 활성 촉진제를 포함하는 비알콜성 지방간염 예방 또는 치료용 약학적 조성물 |
| CN113025720B (zh) * | 2021-04-28 | 2022-12-27 | 深圳市人民医院 | 一种用于检测原发性乳腺弥漫性大b细胞淋巴瘤的标志物及其试剂盒和应用 |
| US20240245664A1 (en) * | 2021-09-08 | 2024-07-25 | The Curators Of The University Of Missouri | Methods of using usp15 inhibitors |
| US20250283174A1 (en) * | 2022-05-16 | 2025-09-11 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation |
| JP2025521543A (ja) | 2022-06-22 | 2025-07-10 | ジュノー セラピューティクス インコーポレイテッド | Ｃｄ１９標的ｃａｒ ｔ細胞のセカンドライン治療のための処置方法 |
| US20260166082A1 (en) | 2022-11-02 | 2026-06-18 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
| KR20260088542A (ko) | 2023-10-06 | 2026-06-12 | 주노 쎄러퓨티크스 인코퍼레이티드 | Gprc5d-표적화 car을 발현하는 세포 요법을 사용한 조합 요법 및 관련 방법 및 용도 |
| WO2025164957A1 (ko) * | 2024-01-31 | 2025-08-07 | 남부대학교산학협력단 | 인간화된 세레브론 넉인 마우스 모델 및 이를 이용한 다발성 골수종 항암화학요법의 효능 평가 방법 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| WO1993018186A1 (en) | 1992-03-04 | 1993-09-16 | The Regents Of The University Of California | Comparative genomic hybridization (cgh) |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7504225B2 (en) | 2005-05-12 | 2009-03-17 | Applied Genomics, Inc. | Reagents and methods for use in cancer diagnosis, classification and therapy |
| US20070099209A1 (en) | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US8445198B2 (en) * | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
| AU2007290407A1 (en) | 2006-08-30 | 2008-03-06 | Celgene Corporation | 5-substituted isoindoline compounds |
| EP2074226A2 (en) * | 2006-09-19 | 2009-07-01 | Novartis AG | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors |
| WO2008137838A2 (en) * | 2007-05-03 | 2008-11-13 | Medimmune, Llc | Interferon alpha-induced pharmacodynamic markers |
| US20090148853A1 (en) * | 2007-12-07 | 2009-06-11 | Schafer Peter H | Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma |
| WO2009149319A2 (en) * | 2008-06-05 | 2009-12-10 | Wyeth | Gene expression profiles associated with asthma exacerbation attacks |
| US20100190656A1 (en) | 2008-08-08 | 2010-07-29 | Integrated Diagnostics, Inc. | Breast Cancer Specific Markers and Methods of Use |
| CA2957226C (en) | 2008-10-29 | 2018-08-14 | Celgene Corporation | Isoindoline compounds for use in the treatment of cancer |
| AU2010236606A1 (en) * | 2009-04-14 | 2011-11-03 | Merck Sharp & Dohme Corp. | Interferon-alfa sensitivity biomarkers |
| US20120134969A1 (en) | 2009-05-25 | 2012-05-31 | Hiroshi Handa | Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells |
| KR101692297B1 (ko) * | 2009-10-20 | 2017-01-04 | 도오쿄 인스티튜드 오브 테크놀로지 | 탈리도마이드 표적 인자를 이용한 스크리닝 방법 |
| SG183257A1 (en) | 2010-02-11 | 2012-09-27 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| CN102959073B (zh) | 2010-04-21 | 2015-08-05 | 普瑞坦医疗产品有限公司 | 采集装置及材料 |
| US20110301102A1 (en) * | 2010-06-07 | 2011-12-08 | Telik, Inc. | Compositions and methods for treating myelodysplastic syndrome |
| US9662319B2 (en) * | 2011-03-11 | 2017-05-30 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing responsiveness to lenalidomide, thalidomide, and/or other thalidomide analogs |
| SI2683384T1 (sl) * | 2011-03-11 | 2016-05-31 | Celgene Corporation | Metode zdravljenja raka z uporabo 3-(5-amino-2-metil-4-okso-4H-kinazolin-3-il)-piperidin-2,6-diona |
| WO2012149299A2 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| US20130042333A1 (en) * | 2011-05-06 | 2013-02-14 | Jean-Gabriel JUDDE | Markers for cancer prognosis and therapy and methods of use |
| US8901110B2 (en) * | 2012-01-13 | 2014-12-02 | Celgene Corporation | Use of biomarkers in methods for the treatment of hepatocellular carcinoma |
| ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
| UA116544C2 (uk) * | 2012-08-09 | 2018-04-10 | Селджин Корпорейшн | Спосіб лікування раку з використанням 3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| CA2908954C (en) | 2013-04-17 | 2021-08-03 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer |
| WO2015077058A2 (en) * | 2013-11-08 | 2015-05-28 | The Broad Institute, Inc. | Compositions and methods for selecting a treatment for b-cell neoplasias |
| BR112016012792A2 (pt) | 2013-12-06 | 2017-08-08 | Celgene Corp | Métodos para o tratamento de cânceres hematológicos e o uso de biomarcadores como um preditor de sensibilidade clínica a terapias imunomoduladoras |
| WO2015085172A2 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| JP2017533727A (ja) | 2014-10-13 | 2017-11-16 | セルジーン コーポレイション | 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用 |
| WO2016196580A1 (en) | 2015-06-02 | 2016-12-08 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
| US20170038387A1 (en) | 2015-08-04 | 2017-02-09 | Celgene Corporation | Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| US20180231561A1 (en) | 2015-08-12 | 2018-08-16 | Celgene Corporation | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| AU2016326499A1 (en) | 2015-09-25 | 2018-04-12 | Celgene Corporation | Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| EP3399980B1 (en) | 2016-01-08 | 2025-07-16 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
-
2014
- 2014-12-05 WO PCT/US2014/068795 patent/WO2015085172A2/en not_active Ceased
- 2014-12-05 IL IL278381A patent/IL278381B2/en unknown
- 2014-12-05 EP EP14868331.1A patent/EP3077548B1/en active Active
- 2014-12-05 CA CA2932120A patent/CA2932120C/en active Active
- 2014-12-05 BR BR112016012795A patent/BR112016012795A2/pt not_active Application Discontinuation
- 2014-12-05 KR KR1020167016778A patent/KR102299801B1/ko active Active
- 2014-12-05 EA EA201691144A patent/EA201691144A1/ru unknown
- 2014-12-05 AU AU2014360328A patent/AU2014360328B2/en active Active
- 2014-12-05 CA CA3206268A patent/CA3206268A1/en active Pending
- 2014-12-05 US US15/101,869 patent/US20160313300A1/en not_active Abandoned
- 2014-12-05 ES ES14868331T patent/ES2903155T3/es active Active
- 2014-12-05 MX MX2016007239A patent/MX386337B/es unknown
- 2014-12-05 JP JP2016536629A patent/JP6573611B2/ja active Active
-
2016
- 2016-06-01 IL IL245981A patent/IL245981B/en active IP Right Grant
- 2016-06-01 PH PH12016501041A patent/PH12016501041A1/en unknown
-
2018
- 2018-04-05 US US15/946,618 patent/US10996215B2/en active Active
-
2019
- 2019-06-28 JP JP2019120643A patent/JP7142612B2/ja active Active
-
2021
- 2021-04-01 US US17/220,377 patent/US20220003749A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018507877A5 (enExample) | ||
| IL278381B1 (en) | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers | |
| JP2019216716A5 (enExample) | ||
| JOP20170045B1 (ar) | مركبات بيريدون رباعية الحلقة كمضادات فيروسية | |
| PE20180232A1 (es) | Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue | |
| MX376106B (es) | Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infección por virus de hepatitis b. | |
| JP2015533176A5 (enExample) | ||
| BR112022012444A2 (pt) | Biomarcadores para terapia contra câncer com o uso de antagonistas de mdm2 | |
| WO2018031818A3 (en) | Substituted nucleosides, nucleotides and analogs thereof | |
| RU2016129472A (ru) | Бициклические гетероциклические соединения и их применение в терапии | |
| MY188114A (en) | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection | |
| MX2016009828A (es) | Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b. | |
| EA201990628A1 (ru) | 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний | |
| EA201400624A1 (ru) | Замещенные 4-фенилпиридины для лечения болезней, связанных с рецептором nk-1 | |
| JP2017515815A5 (enExample) | ||
| JP2016530268A5 (enExample) | ||
| MX383929B (es) | Derivados y métodos de tratamiento de las infecciones por hepatitis b. | |
| GEP20247600B (en) | B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | |
| PH12017501007A1 (en) | Compositions comprising 2-((1-(2 - (4-fluorophenyl) -2- oxoethyl) piperidin-4-yl) methyl) isoindolin-1-one for treating schizophrenia | |
| EP4053289A4 (en) | METHOD FOR PRODUCING FROCTOLIGOSACCHARIDES CONTAINING KESTOSE | |
| JP2016523260A5 (enExample) | ||
| FI4080209T3 (fi) | Menetelmä ihmisillä käytettävän immuunivasteen muuntavan lääkkeen toksisuuden määrittämiseksi | |
| JP2018506302A5 (enExample) | ||
| NZ722345A (en) | Pyrazolone compounds and uses thereof | |
| EP3647357A4 (en) | ETHYLENE-VINYL ALCOHOL COPOLYMER COMPOSITION FOR MELT MELTING, PELLET AND MULTILAYERED STRUCTURE |